Communiqués Cidara Therapeutics, Inc.

Actions

CDTX

US1717572069

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 27/06/2024			Varia. 5j.	Varia. 1 janv.
11,19 ^USD	-0,09%		-4,36%	-29,53%

15/05	Cidara Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
25/04	Les plus fortes hausses du prémarché	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference	30/05	AQ
Cidara Therapeutics: Q1 Earnings Snapshot	15/05	AQ
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	15/05	AQ
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules	15/05	AQ
CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX	11/05	PR
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024	26/04	AQ
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX	25/04	BU
CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE	25/04	AQ
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million	24/04	AQ
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline	24/04	AQ
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	22/04	AQ
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice	22/04	AQ
Cidara Therapeutics Announces Reverse Stock Split	22/04	AQ
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024	05/04	AQ
CIDARA THERAPEUTICS TO PRESENT PRECLINCAL DATA ON MULTIPLE NOVEL DRUG-FC CONJUGATE CANDIDATES AT AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2024	07/03	AQ
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024	06/03	AQ
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO	12/02	AQ
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults	29/01	AQ
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults	22/12	AQ
Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress	07/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Cidara Therapeutics, Inc.

Actions

CDTX

US1717572069

Communiqués

Filtres